HYPOPhosphatemia in the Intensive Care: A One-day Point Prevalence Survey

NCT ID: NCT04201899

Last Updated: 2021-02-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

890 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-09

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The point prevalence survey aims at defining the until now unknown real prevalence of hypophosphatemia (defined as blood phosphate value \< 0.8 mmol/l) in international critical care settings

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The survey will be conducted on one single day in each centre (D-day), within a week defined by the project coordinator (International PI). On D-Day, the local investigators will be asked

1. to complete questions aiming at describing their ICU (number of beds, number of patients present on D-Day, type medical/surgical/other, local phosphate reference value, presence of an hypophosphatemia treatment protocol in the ICU and route of phosphate delivery in case of hypophosphatemia)
2. to indicate how many patients had a blood phosphate \<0.08 mmol/l, for each patient with hypophosphatemia, to record the exact lowest value on D-Day, and to record age, number of days in ICU on D-Day, presence (or not) of artificial nutrition and continuous renal replacement therapy, if any phosphate administration is ongoing Data will be recorded in and electronic Case Report Form (e-CRF) in REDCap, and analysed with descriptive statistics No outcome data will be recorded (pure point-prevalence) There is no intervention

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critically Ill

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention - pure observation

Phosphate administration (yes or no)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

\-
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Society of Intensive Care Medicine

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mette M Berger

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mette M BERGER, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Lausanne University Hospital, Lausanne, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tartu University Hospital

Tartu, , Estonia

Site Status

Hôpital Pasteur 2

Nice, , France

Site Status

Lausanne University Hospital

Lausanne, Canton of Vaud, Switzerland

Site Status

Hôpital de Nyon

Nyon, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Estonia France Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Berger MM, Appelberg O, Reintam-Blaser A, Ichai C, Joannes-Boyau O, Casaer M, Schaller SJ, Gunst J, Starkopf J; ESICM-MEN section. Prevalence of hypophosphatemia in the ICU - Results of an international one-day point prevalence survey. Clin Nutr. 2021 May;40(5):3615-3621. doi: 10.1016/j.clnu.2020.12.017. Epub 2020 Dec 29.

Reference Type DERIVED
PMID: 33454128 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-021-406

Identifier Type: OTHER

Identifier Source: secondary_id

CER2019-02343

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Efficient PICU Fluid Care Evaluation
NCT06644508 NOT_YET_RECRUITING NA